Healthy Adults Antioxidant effect, anti-inflammatory effect, blood flow promotion, etc. Healthy Adults
Conditions
Interventions
1) 0 mg of wine processing residue powder
2) Products containing 100mg of wine processing residue powder
3) Products containing 300 mg of wine processing residue powder
Dose frequency: 2 capsules once
Wine processing residue
Sponsors
Hida Noriko
Tsukada Mana
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Persons who meet all of the following criteria shall be eligible. 1) Persons who are between 40 and 60 years of age at the time consent is obtained. 2) Female 3) Persons who are capable of consenting, abide by the rules of compliance during participation in the research, undergo the preliminary examination specified in the research protocol, and are able to report subjective symptoms, etc. 4) Persons who have been judged by the physician in charge of the research to be eligible to participate in this study based on the preliminary examination specified in the research protocol.
Exclusion criteria
Exclusion criteria: Persons who have any of the following will not be included in this study 1) Persons with a history of drug abuse or dependence, alcohol abuse or dependence, or heart, liver, renal, pulmonary, ocular, or hematologic disease that may affect the safety or the evaluation of this study. 2) Patients who are taking drugs (including dietary supplements and dietary supplements) that may affect the evaluation and safety of this study. 3) Have a history of drug allergy 4) Persons who regularly use excessive amounts of alcohol (those who cannot maintain abstinence from alcohol during the study period) 5) Those who are within 3 months of participating in another clinical research study 6) Other subjects who are judged by the investigator to be ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in whitening (spots) index at the end of the treatment periodPercentage change in self-assessment and amount of change in the pre- and post-treatment questionnaires | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the rate and amount of change in skin beauty, mental stress, joint pain, and pre- and post-dose questionnaires at the end of the treatment period. | — |
Contacts
Public ContactNoriko Hida
Clinical Research Institute for Clinical Pharmacology and Therapeutics Showa University
Outcome results
None listed